Fibrotic diseases involve a loss of fat or lipid-filled cells in several organs including the lungs, liver, and skin in addition to expansion of extracellular matrix (ECM). Dermal fibrosis including excess scarring, scleroderma, and eczema, affects about 40 million people, yet there are no therapies for its reversal. Skin is unique among fibrotic organs due to its accessibility and distinct fat compartment, called dermal white adipose tissue (DWAT). Reduced lipid among mature adipocytes which comprise the DWAT has implications for their many functions. The mechanisms governing fibrotic DWAT lipid depletion and the effects of lipid depletion are not known. Wnt signaling is dysregulated among fibrotic tissues and sustained Wnt signaling in mouse dermis is sufficient to cause dermal fibrosis including DWAT lipid depletion through previously unknown mediators. Here we test the following hypothesis: Induced Wnt signaling stimulates lipid breakdown via dipeptidyl peptidase 4 (DPP4) in dermal adipocytes impacting ECM expansion. Using an inducible and reversible genetic mouse model of dermal Wnt activation, we identify cellular mechanisms of lipid depletion and recovery. Wnt activation leads to breakdown of intracellular lipid in DWAT, stimulation of the lipolytic axis, and increased ECM remodeling, all of which recover during reversal. Genetic ablation of candidate Wnt-responsive factor, DPP4, in our model leads to DWAT preservation, attenuated lipid breakdown, diminished ECM remodeling, and reduced dermal thickening. Finally, chemical inhibition of DPP4 in our mouse model leads to accelerated recovery of DWAT and dermis. Together these data demonstrate that Wnt-DPP4 modulates lipid homeostasis in adipocytes, impacting neighboring dermal fibroblasts. Thus, our results suggest that treatment of dermal fibrosis with FDA-approved DPP4 inhibitors may effectively target lipid depletion, a new cellular player in fibrosis.
Read full abstract